Table 3 Antibody response against PvMSP-119 at three sites in India
Seroprevalence | Chennai | Nadiad | Rourkela | Total | ||||
|---|---|---|---|---|---|---|---|---|
n/N (%) | 95% CI | n/N (%) | 95% CI | n/N (%) | 95% CI | n/N (%) | 95% CI | |
Overall | 53/66 (80.3) | 68.6–88.4 | 49/92 (53.3) | 42.9–63.4 | 44/76 (57.9) | 46.3–68.7 | 146/234 (62.4) | 56.0–68.4 |
Gender | ||||||||
 Male | 34/41 (82.9) | 67.5–91.9 | 29/60 (48.3) | 35.7–61.2 | 25/45 (55.5) | 40.4–69.7 | 88/146 (60.3) | 52.0–68.0 |
 Female | 19/25 (76.0) | 54.1–89.5 | 20/32 (62.5) | 43.9–78.0 | 19/31 (61.3) | 42.4–77.3 | 58/88 (65.9) | 55.2–75.2 |
Age (years) | ||||||||
 < 15 | 0 | – | 10/20 (50.0) | 27.7–72.3 | 11/25 (44.0) | 25.2–64.7 | 21/45 (46.7) | 32.2–61.7 |
 ≥ 15 | 53/66 (80.3) | 68.6–88.4 | 39/72 (54.2) | 42.4–65.5 | 33/51 (64.7) | 50.3–76.9 | 125/189 (66.1) | 59.0–72.6 |
PCR125/189 (66.1) | ||||||||
 Positive | 31/37 (83.8) | 67.4–92.8 | 42/49 (85.7) | 72.4–93.2 | 15/28 (53.6) | 34.3–71.8 | 88/114 (77.2) | 68.5–84.1 |
 Negative | 22/29 (75.9) | 56.0–88.6 | 7/43 (16.3) | 07.7–31.1 | 29/48 (60.4) | 45.6–73.5 | 58/120 (48.3) | 39.4–57.4 |
Malaria | ||||||||
 Asymptomatic | 24/28 (85.7) | 66.0–94.9 | 25/27 (92.6) | 72.8–98.3 | 12/25 (48.0) | 28.4–68.2 | 61/80 (76.2) | 65.5–84.4 |
 Symptomatic | 7/9 (77.8) | 33.0–96.1 | 17/22 (77.3) | 53.5–90.9 | 3/3 (100) | – | 27/34 (79.4) | 61.6–90.2 |
Parasitaemia | ||||||||
 Low | 23/25 (92) | 70.9–98.2 | 30/35 (85.7) | 68.9–94.2 | 5/10 (50.0) | 18.1–81.9 | 58/70 (82.8) | 71.9–90.1 |
 High | 4/4 (100) | – | 12/13 (92.3) | 53.1–99.2 | 3/7 (42.8) | 9.1–84.9 | 19/24 (79.2) | 56.8–91.7 |